Aardvark Therapeutics to Present at Upcoming Investor Conferences in September
Aardvark Therapeutics (NASDAQ:AARD), a clinical-stage biopharmaceutical company, will present at three major healthcare investor conferences in September 2025. The company, which focuses on developing novel small-molecule therapeutics for metabolic diseases, will participate in the Cantor Fitzgerald Global Healthcare Conference (September 3), Morgan Stanley Global Healthcare Conference (September 8), and H.C. Wainwright Global Investment Conference (September 10).
All presentations will be available via live webcast on the company's website, with recordings accessible for approximately one month afterward.
Aardvark Therapeutics (NASDAQ:AARD), azienda biofarmaceutica in fase clinica, presenterà a tre importanti conferenze per investitori del settore sanitario a settembre 2025. L’azienda, che si dedica allo sviluppo di nuovi terapeutici a piccola molecola per le malattie metaboliche, parteciperà al Cantor Fitzgerald Global Healthcare Conference (3 settembre), al Morgan Stanley Global Healthcare Conference (8 settembre) e al H.C. Wainwright Global Investment Conference (10 settembre).
Tutte le presentazioni saranno trasmesse in diretta via webcast sul sito web dell’azienda e le registrazioni saranno disponibili per circa un mese dopo la trasmissione.
Aardvark Therapeutics (NASDAQ:AARD), una compañía biofarmacéutica en fase clínica, presentará en tres importantes conferencias de inversores del sector sanitario en septiembre de 2025. La empresa, centrada en el desarrollo de nuevos terapéuticos de pequeñas moléculas para enfermedades metabólicas, participará en la Cantor Fitzgerald Global Healthcare Conference (3 de septiembre), la Morgan Stanley Global Healthcare Conference (8 de septiembre) y la H.C. Wainwright Global Investment Conference (10 de septiembre).
Todas las presentaciones se emitirán en directo por webcast en la web de la compañía y las grabaciones estarán accesibles durante aproximadamente un mes después.
Aardvark Therapeutics (NASDAQ:AARD)는 임상 단계의 바이오제약 기업으로 2025년 9월에 열리는 세 곳의 주요 헬스케어 투자자 콘퍼런스에서 발표를 진행합니다. 대사 질환용 신규 소분자 치료제 개발에 주력하는 이 회사는 Cantor Fitzgerald Global Healthcare Conference(9월 3일), Morgan Stanley Global Healthcare Conference(9월 8일), H.C. Wainwright Global Investment Conference(9월 10일)에 참가합니다.
모든 발표는 회사 웹사이트를 통해 라이브 웹캐스트로 제공되며, 녹화 영상은 방송 후 약 한 달 동안 시청할 수 있습니다.
Aardvark Therapeutics (NASDAQ:AARD), une société biopharmaceutique en phase clinique, présentera lors de trois grandes conférences d'investisseurs du secteur de la santé en septembre 2025. L'entreprise, qui se concentre sur le développement de nouveaux traitements par petites molécules pour les maladies métaboliques, participera à la Cantor Fitzgerald Global Healthcare Conference (3 septembre), à la Morgan Stanley Global Healthcare Conference (8 septembre) et à la H.C. Wainwright Global Investment Conference (10 septembre).
Toutes les présentations seront diffusées en direct via webcast sur le site web de la société, et les enregistrements seront accessibles pendant environ un mois après diffusion.
Aardvark Therapeutics (NASDAQ:AARD), ein biopharmazeutisches Unternehmen in klinischer Phase, wird im September 2025 auf drei großen Healthcare-Investorenkonferenzen präsentieren. Das Unternehmen, das sich auf die Entwicklung neuartiger niedermolekularer Therapeutika für Stoffwechselerkrankungen konzentriert, nimmt an der Cantor Fitzgerald Global Healthcare Conference (3. September), der Morgan Stanley Global Healthcare Conference (8. September) und der H.C. Wainwright Global Investment Conference (10. September) teil.
Alle Präsentationen werden per Live-Webcast auf der Website des Unternehmens verfügbar sein; Aufzeichnungen sind etwa einen Monat lang abrufbar.
- None.
- None.
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the following conferences during September:
- Cantor Fitzgerald Global Healthcare Conference 2025 in New York
Presentation: Wednesday, September 3 at 11:30 a.m. ET
- Morgan Stanley 23rd Annual Global Healthcare Conference in New York
Presentation: Monday, September 8 at 7:00 a.m. ET
- H.C. Wainwright 27th Annual Global Investment Conference in New York
Presentation: Wednesday, September 10 at 10:30 a.m. ET
Live webcasts of each presentation will be accessible on the company’s website, www.aardvarktherapeutics.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.
About Aardvark Therapeutics, Inc.
Aardvark is a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of PWS and metabolic diseases. Recognizing hunger (the discomfort from not having eaten recently) is a distinct neural signaling pathway separate from appetite (the reward-seeking, desirability of food), our programs explore therapeutic applications in hunger associated indications and potential complementary uses with anti-appetite therapies. Our lead compound, oral ARD-101, is in Phase 3 clinical development for the treatment of hyperphagia associated with PWS, a rare disease characterized by insatiable hunger. ARD-101 is also being studied in hypothalamic obesity. Aardvark is also developing ARD-201, a fixed-dose combination of ARD-101 with a DPP-4 inhibitor, with a goal of addressing some of the limitations of currently marketed GLP-1 therapies for the treatment of obesity and obesity-related conditions. For more information, visit aardvarktherapeutics.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning: Aardvark’s business strategy, product candidates, ongoing clinical trials, planned clinical trials, likelihood of success, as well as plans and objectives of management for future operations. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to potential delays in the commencement, enrollment and completion of clinical trials; the risk that we may use our capital resources sooner than expected and that they may be insufficient to allow us to achieve our anticipated milestones; risks related to our dependence on third parties for manufacturing, shipping and clinical and preclinical trials; the risk that results from earlier clinical trials and preclinical studies may not necessarily be predictive of future results; and other risks and uncertainties, including the factors described under the “Risk Factors” section of Aardvark’s Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q that the Company has filed or may subsequently file with the Securities and Exchange Commission. When evaluating Aardvark’s business and prospects, careful consideration should be given to these risks and uncertainties. Any forward-looking statements contained in this press release are based on the current expectations of Aardvark’s management team and speak only as of the date hereof, and Aardvark specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
Carolyn Hawley, Inizio Evoke Comms
(619) 849-5382
Carolyn.hawley@inizioevoke.com
FAQ
When is Aardvark Therapeutics (AARD) presenting at the Cantor Fitzgerald Conference 2025?
How can investors access Aardvark Therapeutics' (AARD) September 2025 conference presentations?
What is Aardvark Therapeutics' (AARD) main focus as a company?
Which investor conferences will Aardvark Therapeutics (AARD) attend in September 2025?
